MSN Says Novartis Recycles Arguments to Delay Generic Entresto

MSN Laboratories Ltd. urged a federal judge to reject Novartis AG’s renewed bid to block its launch of Entresto copies, arguing it recycles rejected arguments and flawed science.

“Novartis’s motion is a regurgitation of its post-trial briefing and last year’s failed preliminary-injunction motion,” MSN said in its June 27 response to Novartis’ second injunction request based on US Patent No. 11,096,918 in the US District Court for the District of Delaware. A ruling granting the motion by July 15—when pediatric exclusivity tied to a different patent expires—could delay US Food and Drug Administration approval of MSN’s generic until November 2026. ...